These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21565498)

  • 41. Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).
    Takeuchi CS; Kim BG; Blazey CM; Ma S; Johnson HW; Anand NK; Arcalas A; Baik TG; Buhr CA; Cannoy J; Epshteyn S; Joshi A; Lara K; Lee MS; Wang L; Leahy JW; Nuss JM; Aay N; Aoyama R; Foster P; Lee J; Lehoux I; Munagala N; Plonowski A; Rajan S; Woolfrey J; Yamaguchi K; Lamb P; Miller N
    J Med Chem; 2013 Mar; 56(6):2218-34. PubMed ID: 23394126
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.
    Mehrotra MM; Heath JA; Smyth MS; Pandey A; Rose JW; Seroogy JM; Volkots DL; Nannizzi-Alaimo L; Park GL; Lambing JL; Hollenbach SJ; Scarborough RM
    J Med Chem; 2004 Apr; 47(8):2037-61. PubMed ID: 15056002
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessment of the putative binding conformation of a pyrazolopyridine class of inhibitors of MAPKAPK2 using computational studies.
    Miglani R; Cliffe IA; Voleti SR
    Eur J Med Chem; 2010 Jan; 45(1):98-105. PubMed ID: 19850376
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
    J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.
    Yao W; Zhuo J; Burns DM; Xu M; Zhang C; Li YL; Qian DQ; He C; Weng L; Shi E; Lin Q; Agrios C; Burn TC; Caulder E; Covington MB; Fridman JS; Friedman S; Katiyar K; Hollis G; Li Y; Liu C; Liu X; Marando CA; Newton R; Pan M; Scherle P; Taylor N; Vaddi K; Wasserman ZR; Wynn R; Yeleswaram S; Jalluri R; Bower M; Zhou BB; Metcalf B
    J Med Chem; 2007 Feb; 50(4):603-6. PubMed ID: 17256836
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.
    Charrier JD; Durrant SJ; Golec JM; Kay DP; Knegtel RM; MacCormick S; Mortimore M; O'Donnell ME; Pinder JL; Reaper PM; Rutherford AP; Wang PS; Young SC; Pollard JR
    J Med Chem; 2011 Apr; 54(7):2320-30. PubMed ID: 21413798
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
    J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel 1-(2-aminopyrazin-3-yl)methyl-2-thioureas as potent inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2).
    Lin S; Lombardo M; Malkani S; Hale JJ; Mills SG; Chapman K; Thompson JE; Zhang WX; Wang R; Cubbon RM; O'Neill EA; Luell S; Carballo-Jane E; Yang L
    Bioorg Med Chem Lett; 2009 Jun; 19(12):3238-42. PubMed ID: 19423344
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design, synthesis, and structure-activity relationships of novel spiro-piperidines as acetyl-CoA carboxylase inhibitors.
    Kamata M; Yamashita T; Kina A; Funata M; Mizukami A; Sasaki M; Tani A; Funami M; Amano N; Fukatsu K
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3643-7. PubMed ID: 22560583
    [TBL] [Abstract][Full Text] [Related]  

  • 50. O-linked triazolotriazines: potent and selective c-Met inhibitors.
    Chen F; Wang Y; Ai J; Zhan Z; Lv Y; Liang Z; Luo C; Mei D; Geng M; Duan W
    ChemMedChem; 2012 Jul; 7(7):1276-85. PubMed ID: 22539497
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases.
    Crosignani S; Page P; Missotten M; Colovray V; Cleva C; Arrighi JF; Atherall J; Macritchie J; Martin T; Humbert Y; Gaudet M; Pupowicz D; Maio M; Pittet PA; Golzio L; Giachetti C; Rocha C; Bernardinelli G; Filinchuk Y; Scheer A; Schwarz MK; Chollet A
    J Med Chem; 2008 Apr; 51(7):2227-43. PubMed ID: 18318469
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines.
    Zask A; Verheijen JC; Curran K; Kaplan J; Richard DJ; Nowak P; Malwitz DJ; Brooijmans N; Bard J; Svenson K; Lucas J; Toral-Barza L; Zhang WG; Hollander I; Gibbons JJ; Abraham RT; Ayral-Kaloustian S; Mansour TS; Yu K
    J Med Chem; 2009 Aug; 52(16):5013-6. PubMed ID: 19645448
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel, orally bioavailable gamma-aminoamide CC chemokine receptor 2 (CCR2) antagonists.
    Pasternak A; Marino D; Vicario PP; Ayala JM; Cascierri MA; Parsons W; Mills SG; Maccoss M; Yang L
    J Med Chem; 2006 Aug; 49(16):4801-4. PubMed ID: 16884289
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potency switch between CHK1 and MK2: discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.
    Meng Z; Ciavarri JP; McRiner A; Zhao Y; Zhao L; Reddy PA; Zhang X; Fischmann TO; Whitehurst C; Arshad Siddiqui M
    Bioorg Med Chem Lett; 2013 May; 23(10):2863-7. PubMed ID: 23587425
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.
    Ramurthy S; Subramanian S; Aikawa M; Amiri P; Costales A; Dove J; Fong S; Jansen JM; Levine B; Ma S; McBride CM; Michaelian J; Pick T; Poon DJ; Girish S; Shafer CM; Stuart D; Sung L; Renhowe PA
    J Med Chem; 2008 Nov; 51(22):7049-52. PubMed ID: 18942827
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis and SAR studies of indole-based MK2 inhibitors.
    Xiong Z; Gao DA; Cogan DA; Goldberg DR; Hao MH; Moss N; Pack E; Pargellis C; Skow D; Trieselmann T; Werneburg B; White A
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1994-9. PubMed ID: 18291646
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.
    Weiss MM; Harmange JC; Polverino AJ; Bauer D; Berry L; Berry V; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Whittington DA; Zanon R
    J Med Chem; 2008 Mar; 51(6):1668-80. PubMed ID: 18324759
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors.
    Goodman KB; Cui H; Dowdell SE; Gaitanopoulos DE; Ivy RL; Sehon CA; Stavenger RA; Wang GZ; Viet AQ; Xu W; Ye G; Semus SF; Evans C; Fries HE; Jolivette LJ; Kirkpatrick RB; Dul E; Khandekar SS; Yi T; Jung DK; Wright LL; Smith GK; Behm DJ; Bentley R; Doe CP; Hu E; Lee D
    J Med Chem; 2007 Jan; 50(1):6-9. PubMed ID: 17201405
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synthesis and structure based optimization of novel Akt inhibitors.
    Lippa B; Pan G; Corbett M; Li C; Kauffman GS; Pandit J; Robinson S; Wei L; Kozina E; Marr ES; Borzillo G; Knauth E; Barbacci-Tobin EG; Vincent P; Troutman M; Baker D; Rajamohan F; Kakar S; Clark T; Morris J
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3359-63. PubMed ID: 18456494
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.